Issues in the Safety Testing of Metabolites

• Prueksaritanont T , LinJH, BaillieTA. Complicating factors in safety testing of drug metabolites. kinetic differences between generated and preformed metabolites.Toxicol. Appl. Pharmacol.217, 143–152 (2006).
   PubMed Web of Science ®Google Scholar
• Leclercq L , CuyckensF, MannensGSet al. Which human metabolites have we MIST? Retrospective analysis, practical aspects and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22, 280–293 (2009).
   PubMed Web of Science ®Google Scholar
• Espina R , YuL, WangJ, TongZ, VashishthaSet al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299–310 (2009).
   PubMed Web of Science ®Google Scholar
• Athersuch TJ , NicholsonJK, WilsonID. Isotopic enrichment enhancement in metabonomic analysis of UPLC–MS data sets.J. Label. Compd Radiopharm.50, 303–307 (2007).
   Web of Science ®Google Scholar
• Baillie TA . Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.Chem. Res. Toxicol.22, 263–266 (2009).
   PubMed Web of Science ®Google Scholar
• Smith CJ , ShillingfordS, EdgeAMet al. Quantification of the in vitro and in vivo metabolic fates of 2-, 3- and 4-bromobenzoic acids using high temperature LC coupled to ICP–MS and linear ion trap MS. Chromatographia 67N, 673–678 (2008).
   Google Scholar
• Zhu P , TongW, AltonKet al. An accurate-mass-based spectral averaging isotope-pattern-filtering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC–MS data. Anal. Chem. 81, 5910–5917 (2009).
   PubMed Web of Science ®Google Scholar
• Lappin G , StevensL. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.Expert Opin. Drug Metab. Toxicol.4, 1021–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Skerjanec A , BerensonJ, HsuCet al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43, 154–162 (2003)
   PubMed Web of Science ®Google Scholar
• Prakash C , ShafferCL, TremaineLMet al. Application of liquid chromatography–accelerator mass spectrometry (LC–AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab Lett. 1(3), 226–231 (2007).
   PubMedGoogle Scholar
• Anderson S , Luffer-AtlasD, KnadlerMP. Predicting circulating human metabolites. How good are we?Chem. Res. Toxicol.22, 243–256 (2009).
   PubMed Web of Science ®Google Scholar
• Dalvie D , ObachRS, KangPet al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22, 357–368 (2009).
   PubMed Web of Science ®Google Scholar
• Luffer-Atlas D . Unique/major human metabolites: why, how and when to test for safety in animals.Drug Metab. Rev.40, 447–463 (2008).
   PubMed Web of Science ®Google Scholar
• Hilmer SN . ADME-tox issues for the elderly.Expert Opin. Drug Met. Toxicol.4, 1321–1331 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson DE , ParkBK, SmithDA. Ethnic variation in drug response: implications for the developments and regulation of drugs.Curr. Opin. Drug Disc. Devel.11, 29–31 (2008).
   PubMedGoogle Scholar
• Smith DA , ObachRS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance and duration of treatment.Chem. Res.Toxicol.22, 267–279 (2009).
   PubMed Web of Science ®Google Scholar
• Nassar AEF , TalaatRE, TokaneH. Drug interactions: concerns and current approaches.IDrugs10, 47–52 (2007).
   PubMedGoogle Scholar
• Urquhart BL , TironaRG, KimRB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters. Implications for interindividual variability in response to drugs.J. Clin. Pharmacol.47, 566–578 (2007).
   PubMed Web of Science ®Google Scholar
• Klaassen CL , SlittAE. Regulation of hepatic transporters by xenobiotic receptors.Curr. Drug Met.6(4), 309–328 (2005).
   PubMed Web of Science ®Google Scholar
• Martignoni M , GroothuisGM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol.2, 875–894 (2006).
   PubMed Web of Science ®Google Scholar
• Bogaards JJ , BertrandM, JacksonPet al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 30, 1131–1152 (2000).
   PubMed Web of Science ®Google Scholar
• Graham MJ , BellAR, CreweHKet al. mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica. 33, 225–237 (2003).
   PubMed Web of Science ®Google Scholar
• Gao W , JeffreyS, JohnstonJS, MillerDDet al. Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2- hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab. Dispos. 34, 254–260 (2006).
   PubMed Web of Science ®Google Scholar
• Sahi J , KhanKK, BlackCB. Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human.Drug Metab. Lett.2, 176–183 (2008).
   PubMedGoogle Scholar
• Lee S -H, Chiu S-HL, Huskey S-EW. Species differences in N-glucuronidation. Drug Metab. Dispos.26, 838–847 (1998).
   PubMed Web of Science ®Google Scholar
• Katoh M , YokoiT. Application of chimeric mice with humanized liver for predictive ADME.Drug Metab. Rev.39, 145–157 (2007).
   PubMed Web of Science ®Google Scholar
• Inoue T , NittaK, SugiharaKet al. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab. Dispos. 36, 2429–2433 (2008).
   PubMed Web of Science ®Google Scholar
• Kitamura S , NittaK, TayamaYet al. Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab. Dispos. 36, 1202–1205 (2008).
   PubMed Web of Science ®Google Scholar
• Okumura H , KatohM, SawadaTet al. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol. Sci. 97, 533–538 (2007).
   PubMed Web of Science ®Google Scholar
• Naito S , FurutaS, YoshidaTet al. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals. J. Toxicol. Sci. 32, 329–341 (2007).
   PubMedGoogle Scholar
• Baillie TA , CayenMN, FoudaHet al. Drug metabolites in safety testing. PhRMA position paper. Toxicol. Appl. Pcol. 182, 188–196 (2002).
   PubMed Web of Science ®Google Scholar
• Baillie TA . MIST-Reply (Letter to the Editor)Toxicol. Appl.190, 91–92 (2003).
   PubMed Web of Science ®Google Scholar
• Smith DA , ObachRS. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.Drug Metab. Dispos.33, 1409–1417 (2005).
   PubMed Web of Science ®Google Scholar
• Davis-Bruno KL , AtrakchiA. A regulatory perspective on issues and approaches in characterizing human metabolites.Chem. Res. Toxicol.19, 1561–1563 (2006).
   PubMed Web of Science ®Google Scholar
• Handbook of Drug Metabolism (2nd Edition) . PearsonPG, WienkersLC (Eds). Informa Healthcare, London, UK, 37–38 (2008).
   Google Scholar
• Lane EA , LevyRH. Prediction of steady state behavior of metabolite from dosing of parent drug.J. Pharm. Sci.69, 610–612 (1980).
   PubMed Web of Science ®Google Scholar
• Jost LM , GschwindHP, JalavaTet al. Metabolism and disposition of vatalanib (PTK787/ZK-22584) in cancer patients. Drug Met. Disp. 34, 1817–1828 (2006).
   PubMed Web of Science ®Google Scholar
• Zollinger M , WaldmeierF, HartmannSet al. Pimecrolimus: absorption, distribution, metabolism and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab. Dispos. 34, 765–774 (2006).
   PubMed Web of Science ®Google Scholar
• ICH Topic M3 (R2) . Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. CPMP/ICH/286/95. June2009.
   Google Scholar
• Atrakchi AH . Interpretation and considerations on the safety evaluation of human drug metabolites.Chem. Res. Toxicol.22, 1217–1220 (2009).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA. Guidance for Industry: Safety Testing of Drug Metabolites. Center for Drug Evaluation and Research, Rockville, MD, USA (2008).
   Google Scholar
• ICH S7A safety pharmacology studies for human pharmaceuticals www.fda.gov/cder/guidance/4461fnl.pdf
   Google Scholar
• Guidance for industry carcinogenicity study protocol submissions www.fda.gov/cder/guidance/4804fnl.pdf
   Google Scholar
• ICH S9 nonclinical evaluation for anticancer pharmaceuticals, draft guidance www.fda.gov/cder/guidance/8681dft.pdf
   Google Scholar
• Shiew-Mei Huang. Making a decision on drug metabolism data – go or no go. Presented at: AAPS–PPDM round table. San Diego, CA, USA, 12 November 2007 www.fda.gov/cder/drug/druginteractions/presents/2007–2012–2011_huang_20_min_final_bw.pdf
   Google Scholar